Definitely a good tactic selling half or all after a good phase 2 readout. Bios go into sleeper mode as not much happens for a couple of years and you can make money elsewhere. The tide is definitely turning here, and with low SOI the move will be aggressive.
Ann: Invex Granted Key European Patent for Exenatide, page-51
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
